# Angion Biomedica

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/angion-biomedica

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.angion.com
- Total disclosed funding: $6.7M
- Latest round: Series C (Jun 12, 2020)
- Investors on record: 1

## About

Founded in 1998 and based in New York, US, Angion Biomedica Corp. operates as a biotechnology company that develops small molecule targeting therapeutics to treat patients with acute kidney and lung injury related to transplantation COVID-19 related pneumonia. The company raised a total of four funding rounds, according to sec filings. This includes an IPO (Initial Public Offering) prospectus dated March 2014 that was withdrawn in October of the same year. In February 2021, Angion Biomedica Corp. raised USD 117 million in pipe funding from Vifor Pharma Management Ltd.

The company's medical R&D team focuses on discovering, developing, and commercializing small molecule therapeutics to treat acute organ injuries and chronic fibrotic diseases by understanding the HGF (hepatocyte growth factor) and fibrotic pathways involved in tissue repair and organ recovery. The product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor, and CYP11B2 Inhibitor.

The company plans to list on the Nasdaq global select market under the ticker symbol ANGN.

## Funding rounds

- Series C, Jun 12, 2020, $6.7M — Formic Ventures

## Investors

- Formic Ventures (https://capitalatlas.ai/funds/formic-ventures) — Series C